Veterinary preparation possessing antiseptic, reparative and analgesic effect

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation containing myramistin, chitosan and distilled water taken in the following ratio of components, wt.-%: myramistin : chitosan : water = (0.015-0.1):0.2:100, respectively. The preparation shows high effectiveness, strongly expressed wound-healing effect and bactericidal activity and simplicity in using. Invention can be used in treatment of animals with wounds of different etiology and anatomical localization, weeping eczema, burns and others.

EFFECT: valuable medicinal properties of preparation.

1 tbl, 3 ex

 

The invention relates to the field of veterinary medicine and can be used in the treatment of animals with wounds of different etiology and anatomical localization, weeping eczema, burns, etc.

Known drug "Primed"has antiseptic, reparative and soothing action, containing phenol medical, resorcinol, boric acid, chitosan, dimethyl sulfoxide, potassium iodide, glacial acetic acid, glycerin, anesthetic and distilled water (see, for example, RU 2140264, C1, 27.10.1999).

However, in veterinary practice medicine, not been used since for animals has poor efficiency.

The closest is a veterinary drug that has antiseptic, reparative and soothing action, containing antiseptic Miramistin, trimekain and calcium pantothenat (see, for example, RU 2177314, C2, 27.12.2001).

However, when using this drug the healing process is characterized by the duration.

The present invention is to create an efficient means for external use with a wide range of actions.

The problem is solved due to the fact that the drug containing Miramistin, according to the invention further comprises chitosan and distilled water in the following ratio of ingredients (in mA is.%): Miramistin: chitosan: distilled water - 0,015-0,1:0,2: 100.

Technical result provided by the invention, is expressed in the possibility of a complex influence on the affected area of the skin and the resulting high therapeutic effect while reducing undesirable side effects, which leads to shortening of the recovery animals.

The drug was given the name "Magstim".

The invention is illustrated by the following examples, which, however, do not cover, and moreover does not restrict the entire amount of the claims of this invention.

For the preparation of magstim take 0.015 part Miramistin, add 0.2 parts of chitosan and bring to 100 distilled water.

Similarly describes get antiseptic preparation in which the components are in the ratio: Miramistin: chitosan: water is 0.01:0,2: 100 0,1:0,2: 100.

Example 1. In the experience picked up 12 dogs with weeping eczema and divided them into 4 groups: animals 1thgroups were treated with mystimon, in which the ratio of Miramistin, chitosan and water was 0,015:0,2: 100; 2thgroup - mystimon, in which the ratio of Miramistin, chitosan and water - 0,05:0,2: 100; animal 3hergroup - mystimon, in which the ratio of drugs amounted to 0,1:0,2: 100; animals 4thgroups were processed in 0.01% solution of Miramistin.

The effectiveness of pre the proposed comprehensive drug magstim was determined after initial processing, 3, 6 and 9 days.

The effectiveness of the proposed antiseptic medication
no groupMedicationRatioThe effectiveness of healing
3 days6 days9 days
The puffiness covered with a uniform crustsSwelling no, the wound cleanThe skin supple, smooth, painless, observed gains hair
1Magstim0,015:0,2: 100
2Magstim0,05:0,2:100The puffiness covered with a uniform crustsSwelling no, the wound cleanThe skin is smooth, painless, covered with thick scabs
3Magstim0,1:0,2:100The puffiness, painless, takes noThe surface R is HN a clean, well expressed epithelializationBead, stretchy, smooth, there is a dried crust
40,01 cent solution Miramistinthe placeholderThe puffiness, painlessSwelling no, 30% of the surface covered by a thick scabThe skin is smooth, painless, there are detachable hard scabs

Example 2. Under the experience took 10 dogs that underwent surgery. Post-operative wound in the abdominal wall the size of 15-20 cm are treated with a solution of mystigma (0,015:0,2:100) 1 time a day for 10 days. The wound within the first 3 days were purified from detritus and covered with granulations no pathological changes on the background of a slight inflammatory swelling, with 3-day observed phase dehydration, epithelization and scarring from 6-8 days to 9-th day - seam smooth, durable, continuous.

Example 3. Under the experience took 6 cats and 5 dogs with equal stripes of different localization and depth.

All animals were treated with mystimon, in which the ratio of Miramistin, chitosan and water-0,1:0,2:100. Wounds were treated for 5-10 days depending on the depth of the lesion. 3-5 days the wound was clean, had observed the expressed epithelialization, 6-10 day celebrated scarring, the skin is smooth and painless.

M is hstem has a pronounced healing effect, bactericidal activity, easy to use.

Veterinary medicine has antiseptic, reparative and soothing action, containing the Miramistin, characterized in that it further comprises chitosan and distilled water in the following ratio of ingredients, wt.%: Miramistin: chitosan: distilled water - 0,015-0,1:0,2: 100.



 

Same patents:

FIELD: synthesis of biologically active compounds.

SUBSTANCE: invention provides novel urea-substituted imidazoquinoline ethers depicted by general formula I: (1), in which X represents -CHR5- or -CHR5-alkyl group; R1 is selected from radicals: -R4-NR8-CR3-NR5-Z-R6-Alk, -R4-NR8-CR3-NR5-Z-R6-Ph, -R4-NR8-CR3-NR5-Z-R6-furanyl, -R4-NR8-CR3-NR5R-7, phenyl being optionally substituted by one or more substituents selected from methyl, methoxy, methylthio, cyano, hydrogen, dimethylamino, and acetyl; R2 is selected from hydrogen, alkyl, and alkyl-Y-alkyl; R3 represents =O or =S; R4 represents alkyl optionally substituted by one or several O-groups; each of R5 represents C1-C10-alkyl; R6 represents ordinary bond or alkyl; R7 forms cycle together with R5; R4 represents hydrogen, C1-C10-alkyl, or forms morpholine ring together with R8; Y represents -O-; Z ordinary bond, -CO-, or -SO2-; n=0; each of R is independently selected from C1-C10-alkyl, C1-C10-alkoxy, hydroxy, halogen, and trifluoromethyl; or pharmaceutically acceptable salt of forgoing compounds. Described are further compounds of general formula II, intermediates of compounds of general formulae III and IV, pharmaceutical compositions based on compounds I and II, which are immunomodulators for synthesis of cytokines based on compounds I and II, methods of treating viral diseases utilizing compounds I and II, and methods of treating tumor diseases utilizing compounds I and II.

EFFECT: expanded synthetic possibilities in quinoline series and increased choice of therapeutically useful compounds.

25 cl, 4 tbl, 44 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to phenylpyridazine derivative of general formula I , wherein R1 represents C1-C12-alkyl optionally comprising cyclic C3-C6-alkyl structures and optionally substituted by phenyl, which may be substituted by 1-2 halogen atoms; or C1-C12-alkenyl substituted by optionally halogen-substituted phenyl; R2 and R3, independently form each other, represent hydrogen, C1-C12-alkyl, C1-C12-hydroxyalkyl, C1-C12-dihydroxyalkyl, or C1-C12-alkynyl; or R2 and R3, together with adjacent nitrogen atom form 5-6-membered saturated heterocyclic group containing 1-2 nitrogen atoms and optionally oxygen atom, indicated heterocyclic group being optionally substituted by C1-C12-alkyl group, C1-C12-alkoxydicarboxylic group or phenyl-C1-C7-alkyl group; X, Y, and Z, independently form each other, represent hydrogen, halogen, optionally halogen(s)-substituted C1-C12-alkyl, C1-C12-alkoxy, C1-C12-alkylthio, C1-C12-alkylsulfinyl, C1-C12-alkylsulfonyl, or phenyl; and n is a number from 0 to 5; provided that R2 and R3 cannot be simultaneously hydrogen atoms or identical C1-C3-alkyl groups when R1 is benzyl or C1-C3-alkyl group; and salts of compounds I. Foregoing compounds manifest inhibitory activity against production of interleukin IL-1β being well dissoluble in water and characterized by good oral absorption. Invention also relates to therapeutical agent inhibiting production of interleukin 1β, pharmaceutical composition, employment of above-defined compounds, a method for treating disease caused by interleukin 1β production stimulation as well as methods for treating immune system disturbances, inflammatory conditions, ischemia, osteoporosis, or septicemia using above compounds.

EFFECT: expanded therapeutical possibilities.

22 cl, 4 dwg, 2 tbl, 217 ex

FIELD: medicine, gynecology, urology.

SUBSTANCE: on isolating Chlamydia out of infection foci and setting a preliminary diagnosis it is necessary to determine their sensitivity to different etiotropic preparations. Then it is important to sample a patient's blood followed by centrifuging and dividing it into plasma, erythrocytic mass and leukocytic suspension. Removed blood plasma should be substituted with physiological solution, and autoerythrocytes should be returned for a patient in physiological solution intravenously by drops. Autoleukocytic suspension should be activated with laser radiation of He-Ne laser at λ=0.63 mcm. Then it should be supplemented with etiotropic preparation moxyfloxacin to be intravenously injected for a patient. The procedure should be repeated daily for about 10-12 d. The innovation suggested enables to shorten the terms of interrupting the main clinical manifestations of the disease due to a purposeful transport of etiotropic preparation being of higher bacteriological efficiency in leukocytes activated with laser radiation, into primary (urogenital tract) and secondary (extraurogenital) foci of inflammation and, also, decrease side action of chemopreparations due to decreasing their course dosage.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, immunology.

SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical VOV properties expressing proteins preS2-S and HBs virus of hepatitis B virus, the first immunizing dosage corresponds to minimal quantity of viral material being sufficient to obtain weak immune response in the body in case of insignificant at insignificant reactogenicity, and immunizing dosage of the second - maximal quantity of viral material that causes pronounced and prolong immune response in the body at no negative side action. The technique of applying the kit of bivaccine tablets, first, one should use the 1st tablet at minimal dosage of bivaccine, as for the 2nd tablet - with maximal dosage of bivaccine it should be taken till the moment of developing humoral answer (in 7-14 d) after injecting the 1st tablet at minimal immunizing dosage of bivaccine. The innovation enables to create stable immunity.

EFFECT: higher efficiency.

4 cl, 5 ex, 6 tbl

FIELD: veterinary science, virology, biotechnology.

SUBSTANCE: the suggested vaccine contains the suspension of avirulent and purified antigenic material out of the strain N 101 of cattle rotavirus (Research Institute of Animal Protection) obtained in mono-layer culture cells MDBK or SPEV at accumulation degree being 106 viral particles/ml, not less and activity in IEA being 5.0 log2, not less, and target additives: aluminum hydroxide and saponin in efficient ratios. The strain is deposited in collection of FGU VGNKI under registration number - a culture strain N 101 Research Institute of Animal Protection-DEP. The suggested vaccine is highly immunogenic, safe and areactogenic, it is capable to protect cattle stock against epizootic agent of rotaviral infection circulating in Russian territory.

EFFECT: higher efficiency.

14 cl, 9 ex, 10 tbl

FIELD: chemical-pharmaceutical industry.

SUBSTANCE: the suggested preparation contains sweet flag, perforated St.John's wort, common calendula, common yarrow, purple ecchinacea. Decoction should be prepared upon water passed through silver electrodes. The innovation provides decreased side reactions from anti-tuberculosis preparations of toxico-allergic character applied during prolonged period of time.

EFFECT: higher efficiency.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with carrying out standard modes of antibacterial anti-tuberculosis therapy at addition of homeopathic preparation since the 1st d: apis mellifica 6, china officinalis 6, chelidonium majus 6, stannum 6, sanguinaria Canadensis 6, calium bichromicum 6, carbo vegetabilis 6 per 5 granules thrice daily for about 3-4 mo despite meals intake. This provides the reconstruction of affected homeostasis, immunological state, shortens terms of abacillation and closing the cavities of destruction and prevents side reactions as a result of applying anti-tuberculosis preparations.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: medicine, biology.

SUBSTANCE: the present innovation deals with the technology for manufacturing the series of preparations being of immunoregulating action and could be applied for manufacturing vaccines and preparations for the purposes mentioned. It is necessary to dissolve 3000 g sugar in bidistilled water up to saturated syrup to sterilize it due to boiling followed by cooling it up to about 45-50°C, then one should add as a basis 30 g protein bile fraction of two ad more even-toes animals dissolved in 200 g bidistilled water, the mixture should be thoroughly mixed to dry it up to the end in oven drier at 45-50°C, then the mixture should be ground to sterilize the powder obtained that contains a target product with quartz irradiation to be packed into gelatinous capsules NN 1-3 at 0.5-1.5 g dosage. The innovation provides the development of reliable, economically profitable technology for manufacturing native preparations of immunoregulating action that enables to shorten terms of therapy, prolong terms of remission, achieve complete recovery in case of viral diseases and intoxications and decrease lethality percentage in case of the diseases mentioned.

EFFECT: higher efficiency.

6 ex

FIELD: medicine.

SUBSTANCE: the suggested compound being 3,6-dioxocyclohexa-1,4-dien-1,2,4,5-sodium tetra-sulfonate is of antihypoxic and cytoprotector action. Moreover, the composition has been suggested being of anti-grippe action. The composition declared includes remantadin and 3,6-dioxocyclohexa-1,4-dien-1,2,4,5- sodium tetrasulfonate.

EFFECT: the compound mentioned enables to decrease remantadin toxicity during its usage at high dosage during treating the grippe infection.

4 cl, 6 dwg

FIELD: veterinary medicine.

SUBSTANCE: vaccine comprises as antigens cell suspension of pure cultures of a streptococcosus pathogen Streptococcus pneumoniae and an enterococcal pathogen Streptococcus fecalis isolated from suspension and prepared from damages organs of dead nutrias from the local epizootic focus wherein these cultures are grown separately in beef-extract broth with glucose with the concentration of microbial cells 4-5 billions in 1 cm3 and mixed in equal ratio. Also, vaccine comprises formalin and aluminum hydroxide in the following ratio of components, wt.-%: cell suspension of pure culture of streptococcosus pathogen Streptococcus pneumoniae isolated from a local epizootic focus in the nutrient medium with a titer 4-5 microbial cells in 1 cm3, 38.0-41.5; cell suspension of pure culture of enterococcal infection pathogen Streptococcus fecalis isolated from a local epizootic focus in the nutrient medium with a titer 4-5 billions of microbial cells in 1 cm3, 38.0-41.5; glucose, 1.0-2.0; formalin, 1.5-2.0, and aluminum hydroxide, the balance. Vaccine is harmful and possesses high specificity and effectiveness.

EFFECT: valuable properties of vaccine.

1 tbl, 5 ex

FIELD: biotechnology, medicine.

SUBSTANCE: Lactobacillus salivarius strain AH102, AH103, AH105, AH109, or AH110, have probiotic activity and is used in production of probiotic preparation useful in particular in immunization and vaccination procedures. Strain or strains being administrated to subject are useful in prophylaxis or treatment of inflammation activity in gastrointestinal tract, such as inflammatory bowel disease or irritable bowel syndrome, diarrhea disease.

EFFECT: new effective probiotic preparation.

45 cl, 6 dwg, 9 tbl

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to phenylpyridazine derivative of general formula I , wherein R1 represents C1-C12-alkyl optionally comprising cyclic C3-C6-alkyl structures and optionally substituted by phenyl, which may be substituted by 1-2 halogen atoms; or C1-C12-alkenyl substituted by optionally halogen-substituted phenyl; R2 and R3, independently form each other, represent hydrogen, C1-C12-alkyl, C1-C12-hydroxyalkyl, C1-C12-dihydroxyalkyl, or C1-C12-alkynyl; or R2 and R3, together with adjacent nitrogen atom form 5-6-membered saturated heterocyclic group containing 1-2 nitrogen atoms and optionally oxygen atom, indicated heterocyclic group being optionally substituted by C1-C12-alkyl group, C1-C12-alkoxydicarboxylic group or phenyl-C1-C7-alkyl group; X, Y, and Z, independently form each other, represent hydrogen, halogen, optionally halogen(s)-substituted C1-C12-alkyl, C1-C12-alkoxy, C1-C12-alkylthio, C1-C12-alkylsulfinyl, C1-C12-alkylsulfonyl, or phenyl; and n is a number from 0 to 5; provided that R2 and R3 cannot be simultaneously hydrogen atoms or identical C1-C3-alkyl groups when R1 is benzyl or C1-C3-alkyl group; and salts of compounds I. Foregoing compounds manifest inhibitory activity against production of interleukin IL-1β being well dissoluble in water and characterized by good oral absorption. Invention also relates to therapeutical agent inhibiting production of interleukin 1β, pharmaceutical composition, employment of above-defined compounds, a method for treating disease caused by interleukin 1β production stimulation as well as methods for treating immune system disturbances, inflammatory conditions, ischemia, osteoporosis, or septicemia using above compounds.

EFFECT: expanded therapeutical possibilities.

22 cl, 4 dwg, 2 tbl, 217 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying compounds being united selective inhibitors of serotonin reverse capture (5-HT) (SSRI) and agonists of 5-HT1a receptor, especially 1-[4-(5-cyanoindole-3-il)butyl]-4-(2-carbamoyl-benzofuran-5-il)-piperazine or its physiologically acceptable salt, or 3-{4-[4-(4-cyanophenyl)-piperazine-1-il]-butyl}- 1H-indole-5-carbonitrile or its physiologically acceptable salt, in particular, hydrochloride, for manufacturing preparation for treating inflammatory bowel syndrome (IBS) The innovation decreases the symptoms of IBS: spastic pains, meteorism, painful constipation or diarrhea.

EFFECT: higher efficiency.

3 cl, 4 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to cyclopentyl compounds of the general formula (I): wherein X means carbon (C), nitrogen (N) or oxygen (O) atom; Y means O; Z means C; R1 means hydrogen atom, -(C0-C6)-alkyl-W-(C1-C6)-alkyl-, -(C0-C6)-alkyl-W-(C0-C6)-alkyl-(C3-C7)-cycloalkyl-(C0-C6)-alkyl wherein alkyl and cycloalkyl are optionally substituted with 1-7 independent substitutes chosen from hydroxy-group, -O-(C1-C3)-alkyl, trifluoromethyl, (C1-C3)-alkyl; W means a simple bond, -O-, -CO-, -CO2-, -CONR10- or -NR9-; R2 means -(C0-C6)-alkyl, (C0-C6)-alkyl-W-(C1-C6)-alkyl or (C0-C6)-alkyl-W-(C3-C7)-cycloalkyl wherein (C1-C6)-alkyl, (C3-C7)-cycloalkyl are optionally substituted with 1-6 substitutes chosen from halogen atom, trifluoromethyl, -(C1-C6)-alkyl; R3 means hydrogen atom, -(C0-C6)-alkyl-phenyl, -(C0-C6)-alkyl-heterocycle, -(C0-C6)-alkyl-(C3-C7)-cycloalkyl, -(C0-C6)-alkyl-CO2R10, -(C0-C6)-alkyl-(alkene)-CO2R10, -(C0-C6)-alkyl-SO3H, -(C0-C6)-alkyl-W-(C0-C4)-alkyl, -CONR10N10- or -NR10CO2R10-, -NR10-(C0-C3)-alkyl-CO2R10- wherein phenyl and heterocycle, cycloalkyl or (C0-C6)-alkyl are optionally substituted with 1-5 independent substitutes chosen from halogen atom, trifluoromethyl, hydroxy-group, (C1-C3)-alkyl, -O-(C0-C3)-CO2R10, -CN, =O, -NR10R10, -CONR10R10, -SO3-R10 or -(C0-C3)-alkyl-heterocycle and wherein phenyl can be condensed with heterocycle that the latter can be substituted with 1-2 hydroxyl groups; R4 is absent if X represents O or N, or if a double bond joints carbon atoms to which R3 and R6 are added, or R4 means hydroxy-group, -(C0-C6)-alkyl, -CN, -(C0-C3)-CO2R10; or R3 and R4 are combined and form 1H-indenyl, 2,3-dihydro-1H-indenyl, cyclopentanyl or cyclohexanyl ring wherein this obtained cycle is optionally substituted with 1-5 substitutes chosen independently from hydroxy-group, (C1-C3)-alkyl, -O-(C1-C3)-alkyl and -(C0-C3)-CO2R10; or R3 and R5, or R4 and R6 are combined and form phenyl or heterocyclic ring wherein this ring is optionally substituted with 1-7 independent substitutes chosen from hydroxy-group, (C1-C3)-alkyl, -O-(C1-C3)-alkyl, -CO2R10; R5 and R6 mean independently hydrogen atom, hydroxy-group, (C1-C6)-alkyl or (C0-C6)-alkyl-CO2R10; if Z means C then R7 means hydrogen atom, (C1-C6)-alkyl; R8 means hydrogen atom; R10 means hydrogen atom, -(C1-C6)-alkyl, benzyl, phenyl or -(C0-C6)-alkyl-(C3-C6)-cycloalkyl; n1 and n2 = 0, 1 or 2 independently and the sum n1 + n2 = 0, 1, 2 or 3; a dotted line represents a simple or double bond, and other

compounds of this series. Also, invention relates to a pharmaceutical composition modulating activity of chemokine receptors, a method for modulation of activity of chemokine receptors in mammals, and to a method for treatment, improving, regulating or decreasing risk of inflammatory and immunoregulatory disorder or disease. Invention provides synthesis of novel compounds possessing valuable biological properties.

EFFECT: valuable medicinal and biological properties of compounds and pharmaceutical composition.

21 cl, 4 tbl, 81 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel 4-(dipeptidylamino)-piperidine-1-carboxamidines of the general formula (1): or their optical isomers or pharmaceutical acceptable salts wherein R1 is chosen from hydrogen atom (H), lower alkyl, R4-CO wherein R4 means -OCCH2, R5-OCO wherein R means -SO2; R2 is chosen from lower alkyl, cycloalkyl, (C5-C12)-cycloalkylalkyl, phenylalkyl and others; R3 is chosen from H, -OH and group O-lower alkyl; R4 is chosen from H, lower alkyl and phenyl; R5 is chosen from lower alkyl, phenyl and benzyl. Proposed compounds are inhibitors of kallikrein and can be used in treatment of intestine inflammatory disease, arthritis, septic shock, hypotension or cancer.

EFFECT: valuable medicinal properties of compounds.

12 cl, 2 tbl, 60 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to parecoxib sodium salt in crystalline form that possesses properties of selective inhibitor of cyclooxygenase-2 (COX-2) and can be used in treatment of, for example, inflammatory diseases and pain. Proposed crystalline forms show characteristic peaks of powder X-roentgenogram obtained with using Cu-source of radiation and expressed as angles 2θ and chosen from groups consisting of at least values 5.6; 9.6; 11.0 and 14.5 ± 0.2 angle (form A), and 4.2; 8.3; 12.4; 16.7; 17.5; 20.8 and 24.7 ± 0.2 angle (form B), and 8.8; 11.3; 15.6; 22.4; 23.5 and 26.4 ± 0.2 angle (form E) and wherein each form is anhydrous and non-solvated. Also, invention relates to a method for preparing crystalline form A and to a pharmaceutical composition.

EFFECT: improved preparing method, valuable properties of drug.

21 cl, 5 tbl, 12 dwg, 1 sch, 7 ex

FIELD: chemistry of heterocyclic compounds, organic chemistry, medicine, pharmacy.

SUBSTANCE: invention describes compound of the formula (Ib): or pharmaceutically acceptable hydrate of salt of indicated compound wherein R5 means oxygen atom (O); R6 means hydrogen atom (H); X means -CH2-, -CH(OH)(CH2)n- or -CH(NR11R12)- wherein n = 0; R11 and R12 mean independently hydrogen atom or (C1-C9)-alkyl or nitrogen atom (N), either R11 and R12 taken in common form 5-10-membered aromatic or nonaromatic carbocycle wherein 1-4 carbon atoms in ring are replaced independently with N, O or sulfur (S) atom and wherein at least of them represents nitrogen atom; R1, R2, R3, R4, R7, R8, R9 and R10 mean independently hydrogen atom or -A-B wherein A means -SO2-; B means -NZ1Z2, 5-10-membered aromatic or nonaromatic carbocycle wherein 1-4 carbon atoms in ring are replaced independently with N, O or S and wherein any of these atoms is unsubstituted or substituted with one or more groups comprising (C1-C10)-alkyl, (C1-C5)-alkylene-OC(O)-(C1-C5)-alkyl; Z1 and Z2 mean independently H or (C1-C10)-alkyl that is unsubstituted or substituted with one or more groups -N(Z3)(Z4) wherein Z and Z4 mean independently H or (C1-C5)-alkyl that is unsubstituted or substituted with one or more hydroxy-groups; either N, Z3 and Z4 taken in common form unsubstituted or substituted 5-10-membered aromatic or nonaromatic carbocycle wherein 1-4 carbon atoms in ring are replaced independently with N, O or S and wherein one of these atoms represents nitrogen atom.

EFFECT: valuable medicinal properties of compounds.

42 cl, 4 tbl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a method for treatment of a patient with inflammatory disease or risk for its development. Method involves administration to a patient the following drugs: (i) tricyclic antidepressant, for example, amoxapine and (ii) corticosteroid, for example, prednisolon. Medicinal agents (i) and (ii) are administrated simultaneously or in interval in limits for 14 days in doses sufficient for inhibition of inflammation or reducing risk for its development. Also, invention relates to a pharmaceutical composition and pharmaceutical package containing medicinal agents (i) and (ii). Also, invention relates to a method for identification of combinations of compounds used in treatment of inflammation by assay of decreasing levels of pro-inflammatory cytokine in contact of immune cells with the combination of compound-candidate with (i) or (ii). Invention provides expanding assortment of anti-inflammatory agents and combinations, identification of such combinations and reducing toxicity in carrying out the anti-inflammatory treatment.

EFFECT: valuable medicinal properties of combinations, improved method of treatment.

36 cl, 3 tbl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a method for preparing a composition containing ibuprofen that represents active substance possessing anti-inflammatory, analgesic and antipyretic effects. Method involves covering ibuprofen or its salts with hydroxymethylpropylcellulose, methylcellulose, carboxymethylcellulose sodium, hydroxypropylcellulose or gelatin as a binding agent wherein part of binding agent is from 0.1 to 10 wt.-%, and part of ibuprofen or its salts is from 90 to 99.9 wt.-% as measured for dry weight. The composition can be pressed directly to form solid medicinal formulations showing hardness and stability against abrasion, stability in storage and wherein active substance is released in desired time, Medicinal preparation can be used directly for making tablets of different size and with different dose of ibuprofen.

EFFECT: improved preparing method, improved pharmaceutical properties of composition and tablets.

10 cl, 5 tbl, 3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to compounds of the formula (I): possessing properties of inhibitor of inflammatory cytokines release from cells. In compound of the formula (I) R is chosen from: (a) fragment of the formula -OR3 wherein R3 is chosen from group consisting of phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2-cyanophenyl, 3-cyanophenyl, 2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methylphenyl, 4-methylphenyl, 2,4-dimethylphenyl, 3-N-acetylaminophenyl, 2-methoxyphenyl, 4-methoxyphenyl and 3-benzo[1,3]dioxol-5-yl; (b) fragment of the formula: wherein R6 is chosen from group consisting of hydrogen atom, methyl, ethyl, vinyl, cyclopropyl, cyclohexyl, methoxymethyl, methoxyethyl, 1-hydroxy-1-methylethyl, carboxy-group, 4-fluorophenyl, 2-aminophenyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-(propanesulfonyl)phenyl, 3-benzo[1,3]dioxol-5-yl, pyridine-2-yl, pyridine-3-yl, or (c) fragment of the formula: wherein R6 is chosen from group consisting of hydrogen atom, methyl, ethyl, vinyl, cyclopropyl, cyclohexyl, methoxymethyl, methoxyethyl, 1-hydroxy-1-methylethyl, carboxy-group, phenyl, 4-fluorophenyl, 2-aminophenyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-(propanesulfonyl)phenyl, 3-benzo[1,3]dioxol-5-yl, pyridine-2-yl, pyridine-3-yl; each radical R2 is chosen independently from group consisting of (a) hydrogen atom; (b) -(CH2)jO(CH2)nR8; (c) -(CH2)jNR9aR9b; (e) -(CH2)OCO2R10; (g) -(CH2)jOCON(R10)2 wherein each radical R8, R9a, R9b and R10 represents independently hydrogen atom, (C1-C4)-alkyl; or R9a and R9b can form in common 5-6-membered heterocyclic ring comprising 1-2 heteroatoms chosen from nitrogen and/or oxygen atoms; or two radicals R10 can form in common 5-6-membered heterocyclic ring comprising 1-2 heteroatoms chosen from nitrogen and/or oxygen atoms; j represents index 0; n represents index 0. Also, invention relates to a pharmaceutical composition and a method for inhibition.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

15 cl, 2 sch, 8 tbl, 13 ex

FIELD: medicine, endocrinology, ophthalmology, pharmacy.

SUBSTANCE: invention relates to a method for treatment of diabetic retinopathy. Method involves a single administration of 1.0 ml of 2% combined hydrogel solution of chitosan ascorbate with the deacylation degree 94-98% and molecular mass 100-700 kDa and containing 200 mg of hyaluronic acid, 2 g of chondroitin sulfuric acid, 110-440 mcg of cattle serum growth factor and 50 mg of heparin in 1 l of solution through a cannula into the Tenon's space to posterior eye pole. Method provides effective treatment and decrease of adverse effects based on enhancing blood supply of posterior eye pole and anti-allergic properties of biomaterial.

EFFECT: improved method and enhanced effectiveness of treatment.

1 tbl, 1 ex

Up!